Figure 5.
Residual and removed risks of kidney outcomes (generally, sustained decline in eGFR at least 50%, ESKD, and death from renal causes) and major adverse cardiovascular events (MACE) in intensive glucose trials (IGT) and in cardiovascular outcome trials with newer drugs. Dipeptidyl-peptidase-4 inhibitors (DPP-4i), glucagon-like peptide-1 receptor agonist (GLP-1RA), and sodium-glucose transporter-2 inhibitors (SGLT-2i) [102].
